Introduction
The study of the neostriatum—a major component of the basal ganglia—revolves around understanding whether it functions as a single integrated unit or as distinct functional entities. In the original publication titled "The neostriatum: two entities, one structure?" (DOI: 10.1007/s00429-015-1000-4), researchers utilized advanced chemogenetic techniques to manipulate neuronal signaling. Following publication, a systematic typographical error was identified regarding the specific tools used to achieve these manipulations. This erratum serves to correct the scientific record and ensure the clarity of the study's functional conclusions.
The Nature of the Typographical Error
The primary correction concerns the nomenclature of the Designer Receptor Exclusively Activated by Designer Drugs (DREADD) employed in the experiments. Throughout the original article, the inhibitory tool was repeatedly referred to as "hM3Di." The authors have formally clarified that this label was a typographical artifact and that the actual receptor used was hM4Di.
Scientific Significance of DREADD Nomenclature
In modern neuroscience, DREADDs are indispensable for the remote control of cellular signaling. These receptors are engineered to be insensitive to endogenous ligands but highly sensitive to synthetic actuators. Precision in labeling these tools is critical because different DREADD variants exert diametrically opposite effects on cell physiology:
- hM3Dq (Excitatory): This receptor is Gq-coupled. When activated, it typically increases neuronal firing and excitability.
- hM4Di (Inhibitory): This receptor is Gi-coupled. Its activation leads to the hyperpolarization of neurons, effectively silencing or inhibiting their activity.
The term "hM3Di" used in the original paper does not correspond to any existing designer receptor in the standard DREADD toolkit. It appears to be a hybrid typo combining the "hM3" prefix (associated with the excitatory Gq variant) with the "i" suffix (associated with inhibition).
Maintaining Consistency with Functional Results
The authors emphasize that this correction does not alter the study's findings but rather clarifies the mechanism behind them. The original research described the experimental results as inhibitory in nature. Therefore, correcting the nomenclature to hM4Di maintains internal consistency between the reported molecular methods and the observed physiological outcomes.
Readers are cautioned not to assume a "double error"—the study did not use an excitatory receptor (hM3Dq) and misreport the results as inhibitory. Instead, the inhibitory receptor (hM4Di) was used correctly in the lab, but mislabeled during the manuscript preparation process.
Conclusion
Accurate nomenclature is the cornerstone of reproducible science. By identifying the receptor as hM4Di, the authors ensure that the inhibitory control of neostriatal entities is correctly attributed to the Gi-coupled signaling pathway. This correction preserves the integrity of the study's conclusions regarding the structural and functional organization of the neostriatum.
Summary updated